div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: elfosscientiaecigbeducuelfosscientiaecigbeducuPDFsBiotecnol Apl1997143185-188pdf · viduals and predicting progression to ADS 4-9 Among the persons with 1--ÐV infection src=https:reader030vdocumentinreader030viewer20220409085e802d58f6df6521be07a344html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: elfosscientiaecigbeducuelfosscientiaecigbeducuPDFsBiotecnol Apl1997143185-188pdf · viduals and predicting progression to ADS 4-9 Among the persons with 1--ÐV infection src=https:reader030vdocumentinreader030viewer20220409085e802d58f6df6521be07a344html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: elfosscientiaecigbeducuelfosscientiaecigbeducuPDFsBiotecnol Apl1997143185-188pdf · viduals and predicting progression to ADS 4-9 Among the persons with 1--ÐV infection src=https:reader030vdocumentinreader030viewer20220409085e802d58f6df6521be07a344html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: elfosscientiaecigbeducuelfosscientiaecigbeducuPDFsBiotecnol Apl1997143185-188pdf · viduals and predicting progression to ADS 4-9 Among the persons with 1--ÐV infection src=https:reader030vdocumentinreader030viewer20220409085e802d58f6df6521be07a344html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdiv